Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer

27 Nov 2019

Abstract excerpt

Over 80% of triple-negative breast cancers (TNBC) express mutant p53 (mtp53) and some contain oncogenic gain-of-function (GOF) p53. We previously reported that GOF mtp53 R273H upregulates the chromatin association of mini chromosome maintenance (MCM) proteins MCM2-7 and PARP and named this the mtp53-PARP-MCM axis. In this study, we dissected the function and association between mtp53 and PARP using a number of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31776133
DOI: 10.1158/0008-5472.can-19-1036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast CancerPMID 31776133Read ↗

Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer MetastasisSemantic proximity Read ↗

Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4Semantic proximity Read ↗

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatmentSemantic proximity Read ↗

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.Semantic proximity Read ↗

An mRNA expression-based signature for oncogene-induced replication-stressSemantic proximity Read ↗

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.Semantic proximity Read ↗

PARP inhibitors suppress tumours via centrosome error-induced senescence independent of DNA damage response.Semantic proximity Read ↗

Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase InhibitionSemantic proximity Read ↗

Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.Semantic proximity Read ↗

Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres.Semantic proximity Read ↗

p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.